Abstract Library

#4360 Real-world practice patterns of 177Lu-DOTATATE in neuroendocrine tumours: A GTE national survey

Introduction: 177Lu-DOTATATE is a standard treatment for neuroendocrine tumours. Grade 3/4 hematologic toxicity affects about 5-10% of patients, with a 2-4% risk of secondary malignant hematologic disorders.

Conference:

Presenting Author:

Authors: Oziel-Taieb S, Ansquer C, Deshayes E, Haissaguerre M,

Keywords: 177Lu-DOTATATE, haematological toxicity, thrombocytopenia, neuroendocrine tumour, toxicity management,

#4230 Grade ≥3 subacute haematological toxicity with 177Lu-DOTATATE PRRT – Results from LUMEN study

Introduction: Bone marrow toxicity during peptide receptor radionuclide therapy (PRRT), results from radiation damage to haematopoietic tissue. Prospective comprehensive data on subacute haematological toxicity are scarce.

Conference:

Presenting Author: Mileva M

Authors: Mileva M, van Bogaert C, Ameye L, Flamen P, Karfis I,

Keywords: peptide receptor radionuclide therapy, GEP-NET, haematological toxicity,

#3368 Dose-limiting bone marrow toxicities after Peptide Receptor Radionuclide Therapy are sexually dimorphic

Introduction: Peptide receptor radionuclide therapy (PRRT) can cause dose-limiting toxicities (DLTs) of the bone marrow, liver, and kidneys. It is yet unknown whether women and men are equally at risk for these DLTs.

Conference:

Presenting Author: Minczeles N

Authors: Minczeles N, de Herder W, Konijnenberg M, Feelders R, Brabander T,

Keywords: peptide receptor radionuclide therapy, neuroendocrine tumor, haematological toxicity, sex,

#2286 A Randomized Controlled Study Comparing Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEPNET) with 177Lu-DOTATATE Alone and in Combination with Capecitabine

Introduction: PRRT with 177Lu-DOTATATE (LuTate) is an effective treatment option in patients with metastatic or inoperable GEP-NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: van der Zwan W

Authors: Van der Zwan W, Wyld D, Brabander T, Teunissen J, Kam B,

Keywords: PRRT, 177Lu-DOTATATE, Capecitabine, Xeloda, PFS, OS, Toxicity, GEP-NET, RCT, Randomized,

#1098 177Lu Dotatate vs Sequential 177Lu Dotatate and 90Y Dotatate: Treatment Outcomes for PRRT Patients at the Christie - A Clinical Audit

Introduction: The traditional treatment regime of somatostatin receptor positive NETs by molecular radiotherapy was based on single radionuclides (e.g. 90Y Dotatate or 177Lu Dotatate), delivered as multiple cycles to allow normal tissue recovery. However a newer practice of alternating tcycles of 177Lu and Y90 Dotatate was implemented at the Christie following introduction of this regime in some European centres. Subsequent follow up studies have indicated that longer overall survival and reduced loss of kidney function is found in patient cohorts treated with combined 177Lu and 90Y regimes to either 177Lu or 90Y alone.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Tipping J

Authors: Page E, Tipping J, Birch E, Hamilton D, Manoharan P,

Keywords: PRRT, Toxicity, Audit, RM Dose,